Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

B. E. De Galan; S. Zoungas; J. Chalmers; C. Anderson; C. Dufouil; A. Pillai; M. Cooper; D. E. Grobbee; M. Hackett; P. Hamet; S. R. Heller; L. Lisheng; S. MacMahon; G. Mancia; B. Neal; C. Y. Pan; A. Patel; N. Poulter; F. Travert; M. Woodward

doi:10.1007/s00125-009-1484-7

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

B. E. De Galan, S. Zoungas, J. Chalmers, C. Anderson, C. Dufouil, A. Pillai, M. Cooper, D. E. Grobbee, M. Hackett, P. Hamet, S. R. Heller, L. Lisheng, S. MacMahon, G. Mancia, B. Neal, C. Y. Pan, A. Patel, N. Poulter, F. Travert, M. Woodward

Fondazione Istituto Auxologico Italiano

Research output: Contribution to journal › Article › peer-review

Abstract

Aims/hypothesis: The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial. Methods: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n=8,689), 24-27 ('mild dysfunction', n=2,231) and

Original language	English
Pages (from-to)	2328-2336
Number of pages	9
Journal	Diabetologia
Volume	52
Issue number	11
DOIs	https://doi.org/10.1007/s00125-009-1484-7
Publication status	Published - Nov 2009

Keywords

Blood pressure control
Cardiovascular disease risk
Cognitive function
Glucose control
Hypoglycaemia
MMSE
Mortality
Type 2 diabetes

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism

Access to Document

10.1007/s00125-009-1484-7

Fingerprint Dive into the research topics of 'Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial'. Together they form a unique fingerprint.

Cite this

De Galan, B. E., Zoungas, S., Chalmers, J., Anderson, C., Dufouil, C., Pillai, A., Cooper, M., Grobbee, D. E., Hackett, M., Hamet, P., Heller, S. R., Lisheng, L., MacMahon, S., Mancia, G., Neal, B., Pan, C. Y., Patel, A., Poulter, N., Travert, F., & Woodward, M. (2009). Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia, 52(11), 2328-2336. https://doi.org/10.1007/s00125-009-1484-7

Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes : The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial. / De Galan, B. E.; Zoungas, S.; Chalmers, J.; Anderson, C.; Dufouil, C.; Pillai, A.; Cooper, M.; Grobbee, D. E.; Hackett, M.; Hamet, P.; Heller, S. R.; Lisheng, L.; MacMahon, S.; Mancia, G.; Neal, B.; Pan, C. Y.; Patel, A.; Poulter, N.; Travert, F.; Woodward, M.

In: Diabetologia, Vol. 52, No. 11, 11.2009, p. 2328-2336.

Research output: Contribution to journal › Article › peer-review

De Galan, BE, Zoungas, S, Chalmers, J, Anderson, C, Dufouil, C, Pillai, A, Cooper, M, Grobbee, DE, Hackett, M, Hamet, P, Heller, SR, Lisheng, L, MacMahon, S, Mancia, G, Neal, B, Pan, CY, Patel, A, Poulter, N, Travert, F & Woodward, M 2009, 'Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial', Diabetologia, vol. 52, no. 11, pp. 2328-2336. https://doi.org/10.1007/s00125-009-1484-7

De Galan BE, Zoungas S, Chalmers J, Anderson C, Dufouil C, Pillai A et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial. Diabetologia. 2009 Nov;52(11):2328-2336. https://doi.org/10.1007/s00125-009-1484-7

De Galan, B. E. ; Zoungas, S. ; Chalmers, J. ; Anderson, C. ; Dufouil, C. ; Pillai, A. ; Cooper, M. ; Grobbee, D. E. ; Hackett, M. ; Hamet, P. ; Heller, S. R. ; Lisheng, L. ; MacMahon, S. ; Mancia, G. ; Neal, B. ; Pan, C. Y. ; Patel, A. ; Poulter, N. ; Travert, F. ; Woodward, M. / Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes : The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial. In: Diabetologia. 2009 ; Vol. 52, No. 11. pp. 2328-2336.

@article{6fff0a7dfd6d4104a0439494f6a10630,

title = "Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial",

abstract = "Aims/hypothesis: The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial. Methods: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n=8,689), 24-27 ('mild dysfunction', n=2,231) and ",

keywords = "Blood pressure control, Cardiovascular disease risk, Cognitive function, Glucose control, Hypoglycaemia, MMSE, Mortality, Type 2 diabetes",

author = "{De Galan}, {B. E.} and S. Zoungas and J. Chalmers and C. Anderson and C. Dufouil and A. Pillai and M. Cooper and Grobbee, {D. E.} and M. Hackett and P. Hamet and Heller, {S. R.} and L. Lisheng and S. MacMahon and G. Mancia and B. Neal and Pan, {C. Y.} and A. Patel and N. Poulter and F. Travert and M. Woodward",

year = "2009",

month = nov,

doi = "10.1007/s00125-009-1484-7",

language = "English",

volume = "52",

pages = "2328--2336",

journal = "Diabetologia",

issn = "0012-186X",

publisher = "Springer Verlag",

number = "11",

}

TY - JOUR

T1 - Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes

T2 - The action in diabetes and vascular disease: Preterax and diamicron modified release controlled evaluation (ADVANCE) trial

AU - De Galan, B. E.

AU - Zoungas, S.

AU - Chalmers, J.

AU - Anderson, C.

AU - Dufouil, C.

AU - Pillai, A.

AU - Cooper, M.

AU - Grobbee, D. E.

AU - Hackett, M.

AU - Hamet, P.

AU - Heller, S. R.

AU - Lisheng, L.

AU - MacMahon, S.

AU - Mancia, G.

AU - Neal, B.

AU - Pan, C. Y.

AU - Patel, A.

AU - Poulter, N.

AU - Travert, F.

AU - Woodward, M.

PY - 2009/11

Y1 - 2009/11

N2 - Aims/hypothesis: The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial. Methods: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n=8,689), 24-27 ('mild dysfunction', n=2,231) and

AB - Aims/hypothesis: The relationship between cognitive function, cardiovascular disease and premature death is not well established in patients with type 2 diabetes. We assessed the effects of cognitive function in 11,140 patients with type 2 diabetes who participated in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Furthermore, we tested whether level of cognitive function altered the beneficial effects of the BP-lowering and glycaemic-control regimens in the trial. Methods: Cognitive function was assessed using the Mini Mental State Examination at baseline, and defined by scores 28-30 ('normal', n=8,689), 24-27 ('mild dysfunction', n=2,231) and

KW - Blood pressure control

KW - Cardiovascular disease risk

KW - Cognitive function

KW - Glucose control

KW - Hypoglycaemia

KW - MMSE

KW - Mortality

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=70349850941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349850941&partnerID=8YFLogxK

U2 - 10.1007/s00125-009-1484-7

DO - 10.1007/s00125-009-1484-7

M3 - Article

C2 - 19688336

AN - SCOPUS:70349850941

VL - 52

SP - 2328

EP - 2336

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 11

ER -